In particular, the PROTAC field has advanced tremendously in recent years.
Protein degradation, through either proteolysis-targeting chimeric technologies (PROTACs) or molecular glues, is an area of high activity in the private markets. Unlike traditional small-molecule inhibitors that require an accessible catalytic site to block the activity of a protein, degraders can leverage any binding pocket or, in some cases, no binding pockets at all. As such, the modality can target previously undruggable proteins. In particular, the PROTAC field has advanced tremendously in recent years. We are now exploring the nascent space of molecular glues, which could see its historically challenging drug design issues helped by new breakthroughs in the field.